ZTS Zoetis Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1555280 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.0%
TTM net income YoY-5.5%
TTM EPS YoY0.7%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR2.9%
Margins
Gross margin71.4%
Operating margin—
Net margin26.1%
FCF margin24.0%
EBITDA margin—
Returns
ROE57.1%
ROA16.4%
ROIC (approx.)—
Asset turnover0.63x
Leverage & solvency
Liabilities / assets78.1%
Debt / equity2.74x
Current ratio2.35x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue5.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B |
| Cost of revenue | $2.67B | $2.72B | $2.56B | $2.45B | $2.30B |
| Gross profit | $6.80B | $6.54B | $5.98B | $5.63B | $5.47B |
| R&D expense | $698.00M | $686.00M | $614.00M | $539.00M | $508.00M |
| SG&A expense | $2.38B | $2.32B | $2.15B | $2.01B | $2.00B |
| Interest expense | $222.00M | $225.00M | $239.00M | $221.00M | $224.00M |
| Pretax income | $3.36B | $3.13B | $2.94B | $2.66B | $2.49B |
| Income tax | $687.00M | $637.00M | $596.00M | $545.00M | $454.00M |
| Net income | $2.67B | $2.49B | $2.34B | $2.11B | $2.04B |
| EPS (basic) | 6.03 | 5.47 | 5.08 | 4.51 | 4.29 |
| EPS (diluted) | 6.02 | 5.47 | 5.07 | 4.49 | 4.27 |
| Dividends declared per share | 2.03 | 1.80 | 1.56 | 1.35 | 1.07 |
| Weighted avg. shares (diluted) | 443.83M | 454.85M | 462.27M | 470.38M | 476.72M |
| Balance sheet | |||||
| Cash & equivalents | $2.45B | $2.11B | $2.04B | $3.58B | $3.48B |
| Short-term investments | $0 | — | — | — | — |
| Receivables | $1.41B | $1.32B | $1.30B | $1.22B | $1.13B |
| Inventory | $2.46B | $2.31B | $2.56B | $2.35B | $1.92B |
| Current assets | $6.77B | $5.99B | $6.34B | $7.51B | $6.93B |
| PP&E, net | $3.69B | $3.39B | $3.20B | $2.75B | $2.42B |
| Goodwill | $2.77B | $2.72B | $2.76B | $2.75B | $2.68B |
| Intangibles | $998.00M | $1.13B | $1.34B | $1.38B | $1.47B |
| Total assets | $15.49B | $14.24B | $14.29B | $14.93B | $13.90B |
| Current liabilities | $2.17B | $3.41B | $1.89B | $3.17B | $1.80B |
| Short-term debt | $0 | $1.35B | $0 | $1.35B | $0 |
| Long-term debt | $9.04B | $5.22B | $6.56B | $6.55B | $6.59B |
| Total debt | $9.04B | $6.57B | $6.56B | $7.90B | $6.59B |
| Total liabilities | $12.07B | $9.47B | $9.29B | $10.52B | $9.36B |
| Shareholders' equity | $3.42B | $4.77B | $5.00B | $4.41B | $4.54B |
| Net debt | $6.59B | $4.46B | $4.52B | $4.32B | $3.11B |
| Shares outstanding | 424.93M | 448.47M | 458.37M | 463.81M | 472.57M |
| Cash flow statement | |||||
| Operating cash flow | $2.90B | $2.95B | $2.35B | $1.91B | $2.21B |
| Capital expenditure | $621.00M | $655.00M | $732.00M | $586.00M | $477.00M |
| Free cash flow | $2.28B | $2.30B | $1.62B | $1.33B | $1.74B |
| Investing cash flow | -$748.00M | -$315.00M | -$777.00M | -$883.00M | -$458.00M |
| Financing cash flow | -$1.87B | -$2.66B | -$3.11B | -$904.00M | -$1.86B |
| Depreciation & amortization | $487.00M | $497.00M | $491.00M | $465.00M | $448.00M |
| Stock-based compensation | $83.00M | $74.00M | $60.00M | $62.00M | $58.00M |
| Share buybacks | $3.23B | $1.86B | $1.09B | $1.59B | $743.00M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.